Single dose vaccination with TNX-801 protects animals from a lethal challenge with monkeypox, the causative agent of mpox TNX ...

Tonix Pharmaceuticals (TNXP) stock gains as the company posts peer-reviewed data for pain drug TNX-102 and new data for mpox ...

TNX-801 is up to 100,000-fold less virulent than live smallpox vaccine strains and a single dose provides robust immunogenicity and protection against mpox and rabbitpox (more than one year) in ...

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) saw its stock rise 2% after unveiling new preclinical findings for its ...

Tonix Pharmaceuticals (NASDAQ:TNXP) announced on Monday an addition to the broad-market Russell 3000 Index and an automatic inclusion in the small-cap Russell 2000 Index. Shares were +0.32% pre-market ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company, announced that Dr. Sina Bavari, Executive Vice President of Infe ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biotech company, announced its inclusion in the Russell 3000® and Russell 2000® Indexes fol ...

Read about Tonix Pharmaceuticals Holding Corp (TNXP:XNAS) stock and today's latest news and financial updates.

Tonix Pharmaceuticals appoints Jim Hunter to its Board, enhancing commercial strategy ahead of TNX-102 SL's potential fibromyalgia launch.

Tonix Pharmaceuticals Holding Corp.* Tonix is a fully-integrated biotechnology company focused on transforming therapies for pain management and vaccines for public health challenges.

Rhumbline Advisers acquired a new stake in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the SEC ...

Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and ...